Modulation of T cell immune functions by the prostaglandin E 2 - CAMP pathway in chronic inflammatory states

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 411-419

  Brudvik, Kristoffer Watten ^a   Taskén, Kjetil ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

cAMP; colorectal cancer; COX 2; Csk; ezrin; HIV; inflammation; PGE2; protein kinase A; T cell

Indexed keywords

ADENOSINE; ANTIRETROVIRUS AGENT; BINDING PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CSK BINDING PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; CYCLOOXYGENASE 2; EZRIN; GLYCOSPHINGOLIPID; HISTAMINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MOESIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIXIN; ROLIPRAM; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; EFFECTOR CELL; ENZYME PHOSPHORYLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOREGULATION; LIPID RAFT; LIVER METASTASIS; LIVER RESECTION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; COLORECTAL NEOPLASMS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOSKELETAL PROTEINS; DINOPROSTONE; HIV INFECTIONS; HUMANS; INFLAMMATION; T-LYMPHOCYTES;

EID: 84859907018     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01800.x     Document Type: Review

References (89)

1. Aandahl EM, Aukrust P, Skalhegg BS, Muller F, Froland SS, Hansson V, et al,. (1998). Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 12: 855-862. (Pubitemid 28294675)
2. Aandahl EM, Aukrust P, Muller F, Hansson V, Tasken K, Froland SS, (1999). Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 13: F109-F114.
3. Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K, et al,. (2002). Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol 169: 802-808. (Pubitemid 34753436)
4. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF, (2004). Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454-2459. (Pubitemid 38228938)
5. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, et al,. (2004). TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173: 4847-4858. (Pubitemid 39387765)
6. Algrain M, Turunen O, Vaheri A, Louvard D, Arpin M, (1993). Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol 120: 129-139.
7. Aricha R, Feferman T, Souroujon MC, Fuchs S, (2006). Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 20: 374-376. (Pubitemid 46671176)
8. Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, Tasken K, et al,. (1999). Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol 162: 1178-1185. (Pubitemid 29035451)
9. Baillie GS, Scott JD, Houslay MD, (2005). Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579: 3264-3270. (Pubitemid 40804673)
10. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, et al,. (2005). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175: 1483-1490. (Pubitemid 41023048)
11. Bjorgo E, Solheim SA, Abrahamsen H, Baillie GS, Brown KM, Berge T, et al,. (2010). Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex. Mol Cell Biol 30: 1660-1672.
12. Bluestone JA, Abbas AK, (2003). Natural versus adaptive regulatory T cells. Nat Rev Immunol 3: 253-257. (Pubitemid 37323210)
13. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al,. (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 1303-1310. (Pubitemid 46919868)
14. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, et al,. (2000). Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 191: 1591-1604. (Pubitemid 30257355)
15. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al,. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371. (Pubitemid 44924494)
16. Bretscher A, Edwards K, Fehon RG, (2002). ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-599.
17. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, et al,. (2005). Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res 11: 4090-4096. (Pubitemid 40791573)
18. Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, Tasken K, (2006). The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 176: 7361-7370. (Pubitemid 43849037)
19. Cadogan M, Dalgleish AG, (2008). Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med 8: 267-271. (Pubitemid 351960979)
20. Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Tasken K, et al,. (2006). Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem 281: 21535-21545. (Pubitemid 44115490)
21. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al,. (2007). Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265. (Pubitemid 46919862)
22. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, et al,. (2002). Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 80: 16-24. (Pubitemid 34143404)
23. Douek DC, Picker LJ, Koup RA, (2003). T cell dynamics in HIV-1 infection. Annu Rev Immunol 21: 265-304. (Pubitemid 37174533)
24. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN, (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188. (Pubitemid 24294584)
25. Essayan DM, (2001). Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671-680. (Pubitemid 33096193)
26. Fujino H, Toyomura K, Chen X, Regan JW, Murayama T, (2011). Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 81: 379-387.
27. Fuld S, Borland G, Yarwood SJ, (2005). Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp Cell Res 309: 161-173. (Pubitemid 41191232)
28. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al,. (2007). Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775. (Pubitemid 46279714)
29. Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R, (2006). Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci 63: 92-99. (Pubitemid 43100284)
30. Giembycz MA, (2008). Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155: 288-290.
31. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, et al,. (2002). Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 29: 346-355. (Pubitemid 34288887)
32. Gloerich M, Bos JL, (2010). Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50: 355-375.
33. Gupta RA, DuBois RN, (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21. (Pubitemid 33741877)
34. Hanoune J, Defer N, (2001). Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41: 145-174. (Pubitemid 32385886)
35. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al,. (2003). Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881-1888. (Pubitemid 37070273)
36. Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, Froland SS, (2003). Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency-involvement of protein kinase A type I. J Immunol 170: 5772-5777. (Pubitemid 36617871)
37. Holm M, Pettersen FO, Kvale D, (2008). PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res 6: 49-58. (Pubitemid 351461021)
38. Huang B, Zhao J, Lei Z, Shen S, Li D, Shen GX, et al,. (2009). miR-142-3p restricts cAMP production in CD4+. EMBO Rep 10: 180-185.
39. Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasken K, (2008). Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem 283: 33708-33718.
40. Johansson CC, Bryn T, Aandahl EM, Areklett MA, Aukrust P, Tasken K, et al,. (2004). Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy. AIDS 18: 951-952. (Pubitemid 38553718)
41. Kammer GM, (1988). The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9: 222-229.
42. Kaupp UB, Seifert R, (2002). Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769-824. (Pubitemid 34743338)
43. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, et al,. (2000). Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404: 999-1003. (Pubitemid 30243594)
44. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR, (2006). T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol 177: 6780-6786. (Pubitemid 44715042)
45. Kraus S, Arber N, (2011). Cancer: do aspirin and other NSAIDs protect against colorectal cancer? Nat Rev Gastroenterol Hepatol 8: 125-126.
46. Kvale D, Aaberge IS, Froland SS, (2002). Predictive value of immunologic parameters and HIV RNA in relation to humoral pneumococcal polysaccharide vaccine responses in patients with HIV infection. Eur J Clin Microbiol Infect Dis 21: 688-690.
47. Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, et al,. (2006). Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS 20: 813-820. (Pubitemid 43731562)
48. Levy FO, Rasmussen AM, Tasken K, Skalhegg BS, Huitfeldt HS, Funderud S, et al,. (1996). Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol 26: 1290-1296.
49. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al,. (2007). Tumor evasion of the immune system by converting CD4+. J Immunol 178: 2883-2892.
50. Loza MJ, Penn RB, (2010). Regulation of T cells in airway disease by beta-agonist. Front Biosci (Schol Ed) 2: 969-979.
51. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM, (2006). FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177: 246-254. (Pubitemid 43939136)
52. Mandapathil M, Whiteside TL, (2011). Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E cooperation. Expert Opin Biol Ther 11: 1203-1214.
53. Mosenden R, Tasken K, (2011). Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell Signal 23: 1009-1016.
54. Mosenden R, Singh P, Cornez I, Heglind M, Ruppelt A, Moutschen M, et al,. (2011). Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol 186: 5119-5130.
55. Nayjib B, Zeddou M, Drion P, Boniver J, Tasken K, Rahmouni S, et al,. (2008). In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice. Open Immunol J 1: 20-24.
56. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, et al,. (2001). Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98: 2736-2744.
57. Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ, Tasken K, (2010). High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. Blood 116: 2253-2265.
58. Pettersen FO, Tasken K, Kvale D, (2010). Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Clin Exp Immunol 161: 315-323.
59. Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, et al,. (2011). An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol 85: 6557-6566.
60. Psaty BM, Potter JD, (2006). Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas. NEJM 355: 950-952. (Pubitemid 44315987)
61. Rahmouni S, Anadahl EM, Trebak M, Boniver J, Tasken K, Moutschen M, (2001). Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to the retrovirus-induced immunodeficiency of mice (MAIDS). A useful in vivo model for drug testing in PKA type I-induced immunodeficiency. FASEB J 15: 1466-1468.
62. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al,. (2006). Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 1498-1506. (Pubitemid 44465514)
63. Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR, et al,. (2007). Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 179: 5159-5168.
64. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al,. (2001). Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32. (Pubitemid 33070205)
65. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al,. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27. (Pubitemid 44116697)
66. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, et al,. (2005). Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220. (Pubitemid 40827331)
67. Sheng H, Shao J, Washington MK, DuBois RN, (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081.
68. Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, Jahnsen T, (1992). Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem 267: 15707-15714.
69. Skalhegg BS, Tasken K, Hansson V, Huitfeldt HS, Jahnsen T, Lea T, (1994). Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science 263: 84-87. (Pubitemid 24076260)
70. Souness JE, Aldous D, Sargent C, (2000). Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127-162. (Pubitemid 30394536)
71. de Souza AP, Bonorino C, (2009). Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9: 1317-1332.
72. Steffensen KD, Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A, (2007). The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 17: 798-807. (Pubitemid 47063320)
73. Stokka AJ, Mosenden R, Ruppelt A, Lygren B, Tasken K, (2010). The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. Biochem J 425: 381-388.
74. Takeuchi S, Takayama Y, Ogawa A, Tamura K, Okada M, (2000). Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem 275: 29183-29186. (Pubitemid 32043785)
75. Tanaka H, Tanaka J, Kjaergaard J, Shu S, (2002). Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25: 207-217. (Pubitemid 34533310)
76. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasken K, (1997). Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem 272: 5495-5500. (Pubitemid 27102370)
77. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, Schraven B, et al,. (2001). Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem 276: 29313-29318.
78. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K, (2002). Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 14: 1-9. (Pubitemid 34020823)
79. Torgersen KM, Aandahl EM, Tasken K, (2008). Molecular architecture of signal complexes regulating immune cell function. Handb Exp Pharmacol 186: 327-363.
80. Torheim EA, Ndhlovu LC, Pettersen FO, Larsen TL, Jha AR, Torgersen KM, et al,. (2009). Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol 39: 1280-1287.
81. Treves AJ, Ligumski M, Fuks Z, Haimovitz A, Rachmilewitz D, (1982). Prostaglandin E2 secretion by subsets of human peripheral blood monocytes. Immunopharmacology 4: 267-276. (Pubitemid 13124601)
82. Tsujii M, Kawano S, DuBois RN, (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340. (Pubitemid 27157312)
83. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S, (1994). ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126: 391-401. (Pubitemid 24226255)
84. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, et al,. (2001). Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193: 497-507. (Pubitemid 32524480)
85. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K, (2003). Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem 278: 17597-17600. (Pubitemid 36799360)
86. Willoughby D, Cooper DM, (2007). Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87: 965-1010. (Pubitemid 47084674)
87. Yaqub S, Tasken K, (2008). Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog 14: 57-77.
88. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA, et al,. (2008). Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 57: 813-821. (Pubitemid 351660125)
89. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S, et al,. (1998). Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140: 885-895. (Pubitemid 28141226)